FMP
Benitec Biopharma Inc.
BNTC
NASDAQ
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
11.58 USD
0.34 (2.94%)
About
ceo
Dr. Jerel A. Banks M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://benitec.comexchange
NASDAQ
Description
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
CIK
0001808898
ISIN
US08205P2092
CUSIP
08205P100
Address
3940 Trust Way
Phone
510 780 0819
Country
US
Employee
16
IPO Date
Jun 24, 2014
Key Executives
